Cernostics

Cernostics, based in Pittsburgh, PA, is a leading precision medicine company specializing in innovative diagnostic tests for various types of cancer, including melanoma, squamous cell carcinoma, and Barrett's esophagus. Their advanced AI-driven tests, such as TissueCypher, provide clinicians with personalized risk scores to accurately predict progression to cancer, enabling tailored treatment plans for patients.

With a focus on precision medicine and cutting-edge technology, Cernostics is dedicated to improving patient outcomes by offering actionable insights based on spatial biology and gene expression profiling. Their tests, like DecisionDx-Melanoma and Diagnostic MyPath Melanoma, empower healthcare providers to make informed decisions and optimize patient care in dermatology, gastroenterology, ophthalmology, and beyond.

Generated from the website